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Abstract 
The GACKIX activator-binding domain has been a compelling target for small 
molecule probe discovery because of the central role activator-GACKIX complexes play 
in diseases ranging from leukemia to memory disorders. Additionally, GACKIX is an 
ideal model to dissect the context-dependent function of activator-coactivator 
complexes. However, the dynamic and transient PPIs formed by GACKIX are difficult 
targets for small molecules. An additional complication is that activator-binding motifs 
such as GACKIX are found in multiple coactivators, making specificity difficult to attain. 
In this study, we demonstrate that the strategy of Tethering can be used to rapidly 
discover highly specific covalent modulators of the dynamic PPIs between activators 
and coactivators. These serve as both orthosteric and allosteric modulators, enabling 
the tunable assembly or disassembly of the activator-coactivator complexes formed 
between the KIX domain and its cognate activator binding partners MLL and CREB. The 
molecules maintain their function and selectivity even in human cell lysates and in 
bacterial cells and thus will ultimately be highly useful probes for cellular studies.  
Introduction  
GACKIX is one of several conformationally plastic domains found in the master 
coactivators CBP and p300.[1, 2] It interacts with more than 15 transcriptional activators 
at two distinct interfaces.[2] NMR studies of GACKIX bound with native transcriptional 
activation domains (TADs) have shown that the endogenous partners such as MLL and 
c-Jun interact at a relatively deeper and smaller site (an area of approximately 900 
Å2)[3, 4] while the transcriptional activation domains of CREB (pKID) and c-Myb interact 
with a shallower and larger surface on the opposite side.[5] The two interfaces are 
allosterically connected such that binding of the transcriptional activation domain of MLL 
enhances the interaction of c-Myb or pKID at the other binding site by approximately 2-
fold.[4, 6] This allosteric enhancement is thought to play a key role in recruitment of 
p300 or CBP to gene promoters.[4, 6, 7] 
The activator-KIX complexes participate in fundamental processes such as 
hematopoiesis and memory formation.[8-10] The discovery of small molecule 
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modulators for those processes has been of high priority in the selection, screening and 
top-down approaches yielding KIX inhibitors.[11-15] One early success identified 
Naphthol AS-E, a molecule that disrupts oncogenic responses in cancer cell models 
with the CREB-GACKIX and Myb-GACKIX complexes as its intended targets.[11, 16, 
17] As this example illustrates, small molecules that target GACKIX have the potential 
to delineate activator-coactivator functions on a phenotypic level. However, even the 
most specific modulators for GACKIX have limited selectivity due to the level of 
redundancy in the protein interaction network.[14, 18-20] These binding surfaces that 
coactivators use to interact with activators are often similar. For instance, the activator 
p53 interacts with GACKIX as well as three other domains within CBP and p300, 
illustrating similarities in these binding surfaces.[21, 22] Finally the GACKIX motif within 
CBP has been found in at least four other eukaryotic coactivators, including the closely 
related p300, but also in unrelated coactivators, such as MED15 and ARC105.[23-25] 
Therefore, even the unusually specific inhibitor sekikaic acid, a natural product that 
exhibits high specificity for the GACKIX domain, has the undesirable potential to target 
other coactivators with this motif in a cellular setting.[14] This severely limits the utility of 
these probe molecules to dissect individual activator-GACKIX interactions and to 
understand their role in normal and pathological processes.[24]  
Recently we reported that the covalent fragment discovery strategy of Tethering 
yields small-molecule modulators for GACKIX termed chemical co-chaperones that 
stabilize distinct conformations of this plastic motif and, in doing so, modulate its ability 
to form binary and ternary complexes.[26] While useful for structural and in vitro 
biophysical studies, these molecules react with GACKIX via disulfide exchange under 
reversible conditions and are thus not usable in more complex environments such as 
those of cells and cell lysates. Here we show, that despite the shallow and poorly 
defined binding surfaces in GACKIX, irreversible covalent co-chaperones highly 
selective for their cognate binding site can be readily accessed by replacement of 
disulfides in the Tethering hits with more reactive moieties (Figure 1). Further, the co-
chaperones show high selectivity for their cognate binding site, even in the presence of 
many potential reactive partners. Finally, changes in the thiophile enable tuning of the 
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assembly behavior of GACKIX, leading to allosteric enhancement or inhibition of binding 
with a subset of partners.  
Results and Discussion 
In a study of the oncogenic K-RAS variant K-RAS(G12C) Shokat and co-workers 
found that inhibitors discovered through Tethering could be converted to irreversible 
modulators via replacement of the disulfide moiety with thiophilic moieties (Nature. 2013 
Nov 28;503(7477):548-51).[27]  Encouraged by these results, we hypothesized that 
disulfide fragments identified in a screen of the CBP/p300 GACKIX motif could serve as 
starting points for irreversible covalent co-chaperones.[28-30] However, specificity of 
the resulting structures was a major concern. The GACKIX motif does not contain 
attractive small molecule binding pockets but rather binding surfaces that are relatively 
featureless. These GACKIX binding surfaces adapt upon interacting with their binding 
partners so the conversion of the disulfide fragments into irreversible co-chaperones 
can be challenging. The irreversible co-chaperones also need to orient the fragment at 
the selected point of Tethering and effectively modulate the cysteine-containing 
GACKIX motif interactions. We chose to start with the GACKIX N627C mutant located 
in proximity to the MLL-binding site because GACKIX N627C mutant had a negligible 
effect on the endogenous GACKIX-binding partners.[30,31] Therefore any alterations in 
the binding of GACKIX to its’ partners was attributed to chemical co-chaperones that 
tethered to this mutant.  
We sought a fragment that is well-known to impact the conformations and 
interactions of the GACKIX motif. The fragment 1-10 tethered to GACKIX N627C stands 
out as both an effective modulator of GACKIX interactions by both inhibiting MLL 
binding (IC50 68 μM)[31] and enhancing pKID binding.[30] Without the tether 1-10 binds 
to the GACKIX motif at the MLL-binding site with modest affinity.[28] 
To initiate the investigation, the disulfide moiety of 1-10 was replaced with three 
distinct thiophiles with or without a glycine linker to produce 1-10a-f.[32-37] These 
molecules were then assessed for dose-dependent alkylation of the GACKIX N627C 
mutant and, as shown in Table 1, the dose-response (DR50) values varied significantly 
with the nature and linkage of thiophilic group. The least effective reactive group in this 
series is the α,β-unsaturated amides including 1-10e and 1-10f, with the labeling of the 
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protein occurring only under forcing conditions. Both 1-10a and 1-10b with an α-chloro 
amide and 1-10c and 1-10e from the vinyl sulfonamide series were more effective, with 
DR50 values ranging from 4.6 - 150 μM.  
The impact of these fragments on GACKIX N627C interactions was considered 
unique because labeling this mutant with the alkylator, iodoacetamide, had minimal 
impact on their affinity (SI Figure 1). When covalently attached to GACKIX each of 
these structures, 1-10a-d, competitively blocked MLL from interacting with its cognate 
binding site analogous to the parent disulfide 1-10. More remarkable are the effects at 
the distal binding site, with fragments 1-10b and 1-10c allosterically inhibiting the 
binding of pKID and 1-10d enhancing the binding nearly 2-fold, comparable to the 
effects observed with the native ligands MLL, and pKID. The affinity differences can be 
reasonably associated with how the 1-10 co-chaperones interact with GACKIX. 
Previously, the 1-10 disulfide was shown to impact the distal site by altering the 
conformational dynamics of GACKIX.[29] Therefore, we hypothesize that the spacing 
between the 1-10 fragment and the reactive group influence the dynamics within 
GACKIX and these structural changes are reflected by how the 1-10 co-chaperones 
effect MLL and pKID binding. 
Assessing target engagement of two 1-10 irreversible probes 
A further examination of the reactivity of the covalent modifiers revealed a 
remarkable degree of selectivity for the MLL-binding site within GACKIX. None of the 
molecules (1-10a-f) react with the KIX domain in the absence of a cysteine residue 
(native GACKIX). In addition, covalent modification selectively occurs only in the MLL-
binding site, even when cysteine residues are introduced around other activator binding 
sites. As shown in Figure 2A, covalent modifiers 1-10a and 1-10d, both of which are 
reactive electrophiles, only form covalent bonds with GACKIX when a cysteine is 
present at the cognate (MLL) binding site. In a more complex environment E. coli 
expressing GACKIX N627C protein was dosed with the irreversible probes and the 
resulting purified protein was qualitatively labeled by the irreversible probes by Q-TOF 
LC-MS (Figure 2B). The affinity of the core scaffold of 1-10 (no electrophilic moiety) has 
been measured as approximately 250 μM; thus, it is unlikely 1-10d at concentrations 
under 10 μM will produce effects due to non-covalent binding interactions.  
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The concern involving irreversible probes is that they may target critical cellular 
components in mammalian cells and cause adverse effects due to their reactivity. 
Preliminary results show that 1-10d readily labels GACKIX N627C in the presence of 
excess glutathione with no observed alkylator-glutathione adducts after one hour, 
suggesting it could function selectively in cells. (SI Figure 2). Thus we decided to 
visualize the potential targets of these probes in a cellular environment. We ventured in 
cells by adding the purified GACKIX N627C mutant to HEK 293T lysate and then dosed 
in a biotinylated variant of the 1-10d probe. Biotin-containing components were pulled-
out of the lysate using NeutrAvidin resin and analyzed by western blot with streptavidin-
HRP (Figure 3). Once again, the 1-10d alkylator displayed significant selectivity for the 
target.  
Conclusion 
The purpose of targeting the GACKIX motif is to understand what roles its 
interactions with activator complexes play in transcriptional events. However, it is 
difficult to distinguish the role of the GACKIX motif in CBP versus p300 function due to 
their significant homology (90%).[38]. From our results the irreversible 1-10 derivatives 
displayed a preference for the cysteine-containing GACKIX N627C mutant. They 
selectively enhance or disrupt interactions between GACKIX N627C and its activators 
only when the cognate cysteine residue is present. Since these probes are irreversible, 
nonspecific targets can drastically weaken their fitness as cellular probes.[36, 43-46] 
Fortunately, our preliminary evidence shows that 1-10d engages the KIX N627C target 
with no prominent, off-targets in different complex environments.  
With our strategy one fragment known as 1-10 was taken from the reversible 
disulfide Tethering screen to provide a framework for a suite of irreversible modulators 
that target the cysteine-containing GACKIX N627C domain. Since the 1-10 irreversible 
co-chaperones target GACKIX in cellular environments, they have the potential to 
examine how GACKIX recognizes different activator binding partners to regulate gene 
expression. Our chemical co-chaperones were able to change the assembly or 
disassembly of GACKIX complexes at the distal site. For instance, 1-10c and 1-10d 
both inhibit MLL but they either disrupt or enhance the pKID-GACKIX interaction. 
Previously our lab showed that the 1-10 tethered to GACKIX N627C prolonged the 
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residence time of pKID to cause the allosteric enhancement. The 1-10 derivatives 
exhibit either positive or negative cooperativity by how they alter the conformational 
dynamics with GACKIX N627C. Finally these co-chaperones, 1-10c and 1-10d could 
also provide novel, contrasting effects on specific pKID (CREB)-dependent genes.  
Studies in cells bearing cysteine mutants of p300 and CBP are a current focus in order 
to connect the biophysically-derived model of GACKIX binding and function with cellular 
function. 
Methods 
Protein Expression and Purification 
As previously described[47], the DNA sequence encoding the GACKIX domain 
from mouse CBP residues 586-672 was cloned into the bacterial expression pRSETB 
vector with an additional hexahistidine tag and a short polar linker fused to the N-
terminus of GACKIX resulting in protein with the sequence (tag and linker residues are 
shown in lower case): 
mrgshhhhhhgmasGVRKGWHEHVTQDLRSHLVHKLVQAIFPTPDPAALKDRRMENLVA
YAKKVEGDMYESANSRDEYYHLLAEKIYKIQKELEEKRRSRL  
The human MED15 KIX cDNA encoding the amino acids 1 through 78 was 
synthesized by GenScript USA, Inc. and cloned into the pET-15b plasmid (Novagen, 
EMD Millipore) using the Nde1 and Xho1 cloning sites. The resulting recombinant wild-
type MED15 KIX protein sequence contained the N-terminal hexahistidine tag and a 
thrombin cleavage site as shown in lower case letters; 
mgsshhhhhhssglvprgsHMDVSGQETDWRSTAFRQKLVSQIEDAMRKAGVAHSKSSKD
MESHVFLKAKTRDEYLSLVARLIIHFRDIHNKKSQASV 
The cysteine mutants at N627, R644, K662, H651, Q609, K606 of CBP GACKIX 
and at R67 and H70 of MED15 GACKIX were generated using site-directed 
mutagenesis as previously described.[28] 
The GACKIX protein was expressed in Rosetta2(DE3) pLysS Escherichia coli 
(Novagen). Cells were grown to an OD600nm of 0.8 - 1.0 (37 
0C, 250 rpm), induced with 
0.25 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) for 4 hours at 25 0C, harvested 
by centrifugation, and stored at -80 0C. The His6-tagged GACKIX protein was affinity 
purified using a batch method with Ni-NTA beads (QIAGEN) following the 
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manufacturer’s instructions and eluted with 400 mM imidazole. GACKIX was polished 
up with ion-exchange chromatography on a Source S column (GE Healthcare) in 50 mM 
phosphate buffer, pH 7.2 eluting with NaCl gradient from 0 to 1 M. Purified protein was 
buffer exchanged into 10 mM sodium phosphate, 100 mM NaCl, pH 6.8 using a PD-10 
column (GE Healthcare) and stored at -80 0C.  
The MED15 KIX (1-78) protein was also expressed in Rosetta2(DE3) pLysS E. 
coli (Novagen). After the cultures reached an OD600nm between 0.8 – 1.0 the cultures 
were cooled to 20 0C and MED15 KIX expression was induced with the addition of 125 
μM IPTG. After 12 to 18 nours, the cells were harvested by centrifugation for 15 minutes 
at at 7,903 xg in a SorvallTM LYNXTM Superspeed Centrifuge with a Fiberlight F6-
6x1000 LEX Carbon Fiber Rotor (ThermoFisher Scientific), collected in a 50 ml falcon 
tube, and stored at -800C. 
The MED15 KIX protein was purified by first suspending bacterial cells in 
approximately 25 ml of lysis buffer (50 mM sodium phosphate, 300 mM NaCl, 5 mM 
imidazole, 1 mM β-ME pH 7.2, cOmplete EDTA-free Protease Inhibitor Cocktail Tablet 
(Roche)). The cells were lysed by sonication at 50% amplitude on ice using a 6 mm tip 
with pulsing cycles of 3 seconds on and 6 seconds off for at least 3 minutes of total 
pulsing time. The soluble lysate was collected by centrifugation for 30 minutes at 9,500 
rpm (9,299 x g) in an Allegra X-22R centrifuge (Beckman Coulter) with a C0650 fixed 
angle rotor, and then incubated with 2 ml of suspended Ni-NTA agarose resin (Qiagen) 
for 1 to 2 hours rotating at 4 oC. The resin was washed with five times with 5 mL of wash 
buffer (50 mM sodium phosphate, 300 mM NaCl, 30 mM imidazole, 1 mM β-ME, pH 
7.2). The nickel-bound protein was eluted with 300 mM imidazole and diluted into 10 
mM sodium phosphate, 100 mM NaCl, 10% glycerol, 0.01% NP-40 pH 6.8. The 
hexahistidine affinity tag was cleaved overnight with Thrombin (Restriction grade, 
Novagen® 69671) according to the manufacturer’s instructions. The cleaved protein 
was further purified on the AKTA FPLC Purifier (GE Healthcare) with the strong cation 
exchanger Source 15S media (GE Healthcare) packed to a 17-ml column volume. After 
loading the sample the column was washed for 1.5 column volumes with buffer A (50 
mM sodium phosphate, 1 mM DTT, pH 6.8). The protein was eluted from the column 
with a gradient of 0% to 60% of buffer B (50 mM sodium phosphate,1 mM DTT, 1 M 
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NaCl, pH 6.8) over four column volumes. Using a 3 kDa molecular weight cut-off 
Amicon Ultra-15 Centrifuge Filter Units (EMD Millipore) the MED15 KIX was 
concentrated and buffer exchanged into 10 mM sodium phosphate, 100 ml sodium 
chloride, 10% glycerol, 0.01% NP-40 pH 6.8. Aliquots of protein were flash frozen in 
liquid nitrogen and stored at -800C. The concentration of the protein was measured 
using absorbance at 280 nm on a NanoDrop 1000 Spectrophotometer (Thermo 
Scientific).  
Peptide Synthesis and Purification  
All peptides were synthesized by standard N-9 Fluorenylmethoxycarbonyl (Fmoc) 
solid phase synthesis methods[48] as previously described.[47] The peptide sequences 
written as single letter amino acid abbreviations are as follows: 
MLL  βA-DAGNILPSDIMDFVLKNTP-CONH2 
pKID  βA-DSQKRREILSRRPS(Phos)YRKILNDLSSDAPG-CONH2 
The abbreviation, βA represents beta-alanine and S(Phos) is phosphoserine. The 
fluorescent fluorescein isothiocyanate (FITC) tag was added at the amino-terminus of 
the peptide before the β-alanine residue.  
DR50 assessment 
For the DR50 values, 5 μM of GACKIX N627C was incubated with varying 
concentrations (500-0.2 μM) of the compounds (at 1 mM β-ME) for 45 minutes at room 
temperature (RT). Then the samples were incubated for 15 minutes at 4 0C. The 
percent of protein tethered to fragment molecules were determined by Q-TOF LC-MS 
(Agilent).[49] The concentration of fragment molecule required for 50% maximum 
Tethering (DR50) was determined in GraphPad Prism software 4.00, fitting to Equation 
1, where x is the log of fragment molecule concentration and y is the normalized 
response from 1 to 100 (percent of protein tethered to fragment molecule).  
  
   
               
        (Eq. 1) 
 
Alkylation of GACKIX 
The GACKIX N627C mutant was incubated with 5 to 10 equivalents of small 
molecule in 10 mM phosphate buffer, 100 mM NaCl, pH 6.8 overnight at room 
temperature. Excess small molecule was removed and small molecule-protein 
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complexes were concentrated using 10 kDa molecular weight cutoff centrifugal 
concentrators (Vivascience). The extent of labeling was measured by Q-TOF LC-MS 
(Agilent). Protein complexes that were at least 95% alkylated were flash frozen in liquid 
nitrogen and stored at -80 0C.  
Fluorescent anisotropy assays  
The fluorescent anisotropy was measured in triplicate with a final sample volume 
of 10 μl in a low volume, non-binding, black, 384-well plate (Corning). For each 
experiment 25 nM of fluorescently labeled peptide tracers, FITC-MLL and FITC-pKID 
were incubated with varying concentrations of the small molecule-GACKIX mutant 
complexes in binding buffer (10 mM phosphate, 100 mM NaCl, pH 6.8) for 30 minutes 
at RT. The plates were read using a Tecan Genios Pro plate reader with polarized 
excitation at 485 nm and emission intensity measured through a parallel and 
perpendicularly polarized 535 nm filter. A binding isotherm that accounts for ligand 
depletion (assuming a 1:1 binding model of peptide to GACKIX) was fit to the observed 
anisotropy values as a function of GACKIX to obtain the apparent equilibrium 
dissociation constant, KD: 
            
[         √              ]
  
    (Eq. 2) 
where “a” and “x” are the total concentrations of fluorescent peptide and GACKIX, 
respectively, “y” is the observed anisotropy at any GACKIX concentration, “b” is the 
maximum observed anisotropy value, and “c” is the minimum observed anisotropy 
value. Data analysis was performed using GraphPad Prism 7.0 software.  
Labeling GACKIX cysteine mutants  
5 μM of cysteine mutants at CBP KIX N627C, N644C, K662C, H651C, Q609C, 
K606C and MED15 KIX R67C, and H70C were incubated with 100 μM of small 
molecule in DMSO in the presence of 1 mM β-ME for 1 hour at RT. The extent of 
labeling was measured by Q-TOF LC-MS (Agilent) and each labeling reaction was 
duplicated.  
Alkylation in growing E. coli 
The protein expression system for the GACKIX N627C protein was initiated as 
described above. Three hours after induction with 0.25 mM IPTG the culture was 
concentrated by centrifugation in which the cell pellet from 50 mL of culture was 
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suspended in 1 mL of media. For a 1 mL alkylation reaction 10 μL of compound in 
DMSO was added to concentrated cells to obtain concentrations of 1000 μM, 500 μM, 
250 μM, 62.5 μM, and 15.6 μM. The mixtures were incubated for 1 hour at 25 0C (250 
rpm). The cell pellets were washed three times with 10 mM phosphate, 100 mM NaCl 
pH 6.8 and stored at -80 0C. Purification was carried out as previously described using 
Ni-NTA resin.[29] The elutions were buffer exchanged into 10 mM phosphate, 100 mM 
NaCl, pH 6.8 and concentrated using 5 kilodalton molecular weight cutoff concentrators 
(Vivascience). The samples were analyzed by Q-TOF LC-MS (Agilent). The extent of 
labeling was determined by comparing the peak intensity of small molecule-GACKIX 
N627C complex versus unlabeled GACKIX N627C. 
NeutrAvidin pull-down assay with the biotinylated 1-10 probe 
HEK 293T cells were maintained in DMEM supplemented with 10% FBS. The 
cells were lysed in 750 µl of lysis buffer (150 mM NaCl, 50 mM Tris (pH 8.0), 0.1% 
Nonidet P-40 (NP-40)) containing halt protease inhibitor cocktail (Thermo Scientific) and 
soluble lysate was isolated by centrifugation (12,000 rpm, 4 0C, 15 min.) HEK 293T 
lysate (100 µg total protein) and 25 nM of purified GACKIX N627C were incubated with 
DMSO or various concentrations of the biotinylated 1-10d probe (5 μM, 1 μM, 200 nM, 
40 nM and 8 nM) at RT for 1 hour. Following incubation with NeutrAvidin agarose resin 
(50 µL, Thermo Scientific) for 1 hour at 4 0C the beads were washed twice with 1 mL of 
wash buffer (10 mM phosphate, 100 mM sodium chloride, 10% glycerol, 0.1% NP-40, 
pH 7.2) and the resin-bound complexes were eluted by boiling in NuPAGE® LDS 
Sample Buffer (Invitrogen) containing DTT. The samples (15 µL) were resolved on a 
12% SDS polyacrylamide gel by electrophoresis. The proteins were transferred onto a 
PVDF membrane and incubated with streptavidin conjugated to hydrogen peroxidase 
(HRP) enzyme (ab7403, Abcam) at 1:10,000 dilution in 10 mM PBS, 0.2% Tween-20. 
The membrane was developed using Amersham ECLTM Prime Western Blotting 































Figure 1  
Schematic for the development of irreversible chemical co-chaperones to target the 
GACKIX domain of CBP. The structure of GACKIX is shown as a cartoon in grey derived 
from PDB ID 4I9O [29]. The black sphere represents the position of the N627C mutant 
that was used to target GACKIX with chemical co-chaperones. The standard Tethering 
scheme involves in the reversible formation of a mixed disulfide with the target when the 
fragment favorably interacts with the regions surrounding cysteine residue. By replacing 
the fragment’s disulfide with an alkylating moiety, the 1-10 chemical co-chaperones 
irreversibly bind to the GACKIX N627C represented in the structure at the far right. 









Table 1  
Comparing irreversible analogues of 1-10 against GACKIX N627C. 
The DR50 values were assessed by measuring the extent of GACKIX 
N627C labeled using Q-TOF LC-MS at various concentrations of 
compound. The fold inhibition values were obtained by comparing the 
dissociation constants (KDs) for the unlabeled (DMSO) KIX N627C 
construct with the KDs for the labeled KIX N627C- 1-10 alkylator 
complex for both the MLL and pKID tracers. The KD values were 
measured from FP experiments that were performed in triplicate and 
errors reflect the standard deviation (SD) error. 
 











A) 1-10a and 1-10d show preference for the GACKIX N627C mutant located near the MLL-
binding site. N644C is located in the loop and the remaining mutants, K662C, H651C, Q609C 
and K606C are located within the pKID-binding site. The error bars represent standard deviation 
of the average of two separate experiments.  B) The 1-10 chemical co-chaperones were dosed 
into E. coli during the expression of GACKIX N627C and after nickel affinity purification, the 
extent of labeling was assessed by LC-MS. The error bars represent standard deviation of the 
average of three values from separate experiments. *0.01 < P < 0.05, **0.05 < P < 




















The structure of the biotinylated 1-10d probe is shown above. This probe was added to 100 µg 
of HEK293T lysate containing purified GACKIX N627C (25 nM). Any biotin-containing proteins 
isolated on NeutrAvidin agarose beads were visualized Western Blot using chemiluminescence 
with Streptavidin- HRP. The bands within the red box represent the expected mass for GACKIX 

























Supplementary Figure 1 The interactions for unlabeled KIX N627 and KIX 
N627C labeled by iodoacetamide (IAM) were compared against the binding 
partners, MLL and pKID using fluorescence polarization (FP) direct binding 
assays. These interactions were not significantly impacted by the presence of IAM 
at the MLL-binding site while some distal effects occurred with pKID binding. All 
measurements were performed in triplicated. The dissociation constants are 
reported with the standard error (SE). The FP direct binding curves are shown for 
the MLL and pKID tracers. The values represent the average and the error bars 
represent the standard deviation (SD). Data analysis was performed in GraphPad 
Prism 7.0. 






Supplementary Figure 2 A) The reactivity of 1-10d toward glutathione was tested by incubating 50 µM of 1-
10d with 500 µM of glutathione in 10 mM sodium phosphate buffer, 100 mM NaCl, pH 6.8 for 45 minutes at 
room temperature. The reaction was injected onto the 1290 Agilent liquid chromatography system equipped 
with a Proshell 300 SB-C8 column and analyzed with the 6545 Agilent quadrupole time-of-flight (Q-TOF) mass 
spectrometer. The mass spectrum is shown with a prominent peak at m/z of 449.0529 corresponding to the 1-
10d sodium adduct (calculated (M+H+Na)+ 449.0526 m/z). Free glutathione eluted off the column first with an 
observed m/z 308.0912 (calculated (M+H)+ 308.0838 m/z) and 330.0731 m/z (calculated (M+H+Na)+ 
330.0736). B) Deconvoluted mass spectrum shows the unbound KIX N627C at 11,921.85 Da.  C) KIX N627C 
(5 µM) was mixed with 50 µM of 1-10d and 500 µM of glutathione for 45 minutes and the reaction was 
analyzed on the Q-TOF LC-MS (Agilent). The mass spectra were deconvoluted using the Agilent MassHunter 
Bioconfirm software (Agilent) and maximum entropy algorithm. KIX N627C was fully labeled by 1-10d with an 
observed deconvoluted mass of 12348.49 Da (calculated mass 12348.69 Da).  
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Supplementary Table S1 The KD values of for MLL and pKID with the unbound (DMSO) 
and labeled GACKIX N627C complexes. The error reflects the standard error from three 
FP experiments.  
 KD (µM) 
Compound MLL pKID 
DMSO 0.32 ± 0.02 0.60 ± 0.04 
1-10a 3.9 ± 0.4 0.52 ± 0.07 
1-10b 4.1 ± 0.2 0.8 ± 0.1 
1-10c 5.4 ± 0.3 0.9 ± 0.1 
1-10d 5.6 ± 0.4 0.40 ± 0.04 
1-10e 4.6 ± 0.5 0.52 ± 0.04 
1-10f 1.47 ± 0.06 0.40 ± 0.04 
 
Supplementary Figure 3 The anisotropy binding curves of the GACKIX N627C bound 
and unbound complexes. The KD values are shown in the supplementary Table 1. All 
measurements were performed in triplicate and analyzed in GraphPad Prism 7.0. The 
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